Infant, Newborn, NRDS
Conditions
Brief summary
Since exogenous surfactant replacement therapy was first used to prevent neonatal respiratory distress syndrome (NRDS),it has become the main method of treatment of NRDS. However, in some infants, death is inevitable despite intensive care and surfactant replacement therapy, especially in near-term and term infants. The first goal of our study is to compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS. The second goal of our study is to further analyze the risk factors and causes of RDS in early preterm infants and near term/term infants.
Interventions
All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
Sponsors
Study design
Eligibility
Inclusion criteria
Infants with RDS who received surfactant therapy were recruited between January 2011 and December 2016.
Exclusion criteria
Infants were excluded if they had any congeni- tal malformation, inherited metabolic abnormality, intrauterine infection, Rh/Rh incompatibility, pneumonia, pulmonary hypertension, meconium aspiration syndrome, or asphyxia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| therapeutic effect of pulmonary surfactant of infants at different gestational ages | January 1,2011 to December 30,2016 |
Countries
China